a menu icon
a back arrow
Sonoma Bio Home

News

The Task Ahead: Translating Cell Therapy into Curative Medicines for Autoimmune Disease

LinkedIn

August 4, 2021
Jeff Bluestone just raised $265M to develop curative cell therapies. We asked him how

Endpoints News

August 4, 2021
Creating T cells to guard against autoimmune disease

Nature

July 14, 2021
Sonoma Biotherapeutics: rallying the regulators

Nature Biotechnology

June 16, 2021
The time is now: Autoimmune and inflammatory diseases, meet regulatory T-cell therapy

LinkedIn

October 1, 2020
Sonoma Bio named as one of most promising startups in biotech by Endpoints News

Endpoints News

September 30, 2020
Jeffrey Bluestone recruits a trio of biopharma vets to the startup team at Sonoma — while adding $30M to the launch round

Endpoints News

September 30, 2020
Foxp3: a genetic foundation for regulatory T cell differentiation and function

Nature Immunology

June 23, 2020
Parker Institute CEO Jeffrey Bluestone Steps Down to Launch Sonoma Biotherapeutics

BioSpace

February 7, 2020
Why the CEO of Sean Parker's cancer institute left to help the 'cellular police' arrest diseases like diabetes

San Francisco Business Times

February 6, 2020
Jeffrey Bluestone steps down as Parker Institute president to develop cell therapies for autoimmune diseases

Stat News

February 7, 2020
Jeffrey Bluestone exits Parker and switches focus back to autoimmune diseases in cell therapy 2.0 launch

Endpoints News

February 6, 2020
HomeMissionCultureTeamSciencePipelineCareersNewsContact
HOMEMissionCultureTeamSciencePipelineCareersInvestorsNewsContact